Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
reyataz
Medication labelWhy this: Advisory · dailymed-prescription
REYATAZ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. • Use of REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see MICROBIOLOGY (12.4)].
- generic_name
- reyataz
- product_names
- REYATAZ
- ndc
- 67296-1236, 0003-3622, 67296-1236-4
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en